

March 9, 2020

✓ **BSE Limited,**
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

The National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards the Company having won the coveted India Pharma Leader Award at the India Pharma 2020 and India Medical Device 2020 conference.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

For **LUPIN LIMITED**


R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)



Encl.: a/a

Lupin wins India Pharma Leader Award at India Pharma 2020 and India Medical Device 2020 Conference

Mumbai, March 9, 2020: Pharma major Lupin Limited (Lupin) won the coveted India Pharma Leader Award at the India Pharma 2020 and India Medical Device 2020 conference.

This was the 5th edition of the event organized by FICCI in collaboration with the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India. Lupin was presented the award by Shri. Vijay Rupani, Chief Minister of Gujarat and Shri. D.V. Sadananda Gowda, Union Minister, Ministry of Chemicals and Fertilizers, Government of India.

Speaking on this win, Nilesh D. Gupta, Managing Director, Lupin said, "We are delighted to receive the India Pharma Leader Award from the Department of Pharmaceuticals, Government of India. It is indeed a moment of pride for us. This award acknowledges our contributions toward strengthening the Indian Pharmaceuticals Market and recognizes our all-round performance."

This year, the event was held at Ahmedabad from March 5 – 7, 2020. The event theme focused on "Clarity on Changing Regulatory Scenarios," and witnessed participation of more than 1,200 delegates from all over India.

About Lupin Limited

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

| Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and Corporate Communications

Email: arvindbothra@lupin.com

Tel: +91 22 6640 8237

Manjira Sharma

General Manager – Corporate Communications

Email: manjirasharma@lupin.com

Tel: +91 22 6640 2532